Patient dies after receiving Intellia's CRISPR therapy
1 day ago · The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. Both phase 3 studies of the candidate remain on hold as the biotech …
Intellia Announces First Clinical Evidence from Ongoing Phase 1 …
Nov 16, 2024 · Nex-z is an investigational in vivo CRISPR-based gene editing therapy in development as a one-time treatment for ATTR amyloidosis. Development and …
Intellia Therapeutics Announces Positive Longer-Term Phase
Sep 25, 2025 · Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron …
FDA places formal hold on two Intellia CRISPR trials
Oct 30, 2025 · The Food and Drug Administration on Wednesday officially put two late-stage trials of a gene-editing treatment from Intellia Therapeutics on hold, adding more complexity to a …
Intellia signals clinical hold for nex-z trials and cash runway ...
1 day ago · Get the latest on Intellia Therapeutics’ Q3 2025 earnings: clinical hold impacts, nex-z safety updates, lonvo-z progress, and financial outlook.
Intellia Initiates Phase 3 Study of Nex-z Gene Therapy for …
Apr 8, 2025 · Intellia Therapeutics (NASDAQ:NTLA) has announced the first patient has been dosed in MAGNITUDE-2, a pivotal, global Phase 3 trial evaluating its one-time gene therapy, …
Intellia’s Promising Longer-Term Nex-Z Data for ATTR ...
Intellia Therapeutics will present longer-term data from its ongoing Phase 1 trial of Nexiguran ziclumeran (Nex-Z), an investigational in vivo CRISPR/Cas9 therapy for hereditary ATTR …
Intellia Therapeutics Announces FDA Regenerative Medicine …
Mar 26, 2025 · Based on Nobel Prize-winning CRISPR/Cas9 technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is an …
Patient dies after receiving Intellia’s CRISPR gene therapy ...
2 days ago · Intellia is working with experts to create a risk management program for nex-z. A patient who developed life-threatening liver complications after being treated with Intellia’s …
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase …
1 day ago · Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin …